Goldman Sachs says this little-known biotech stock can jump more than 50%

Home » Blog » Goldman Sachs says this little-known biotech stock can jump more than 50%

December 20, 2022January 9, 2023

Analyst Chris Shibutani initiated the stock with a buy rating, saying the company has a promising new oral treatment in development for plaque psoriasis.

Previous PostFTX founder Bankman-Fried sent back to Bahamas jail in day of courtroom chaosNext PostThis unusual media stock is a top 2023 play from Morgan Stanley because of growing F1 popularity

Latest Articles

This country may have the fastest-growing e-commerce sector ‘on the planet’
How the Federal Reserve’s rate policy affects mortgages
Banking app Dave, back from the brink, is this year’s biggest gainer among financials with 934% surge
Stocks making the biggest moves midday: Novo Nordisk, Mission Produce, Occidental Petroleum and more
CFPB sues JPMorgan Chase, Bank of America and Wells Fargo over Zelle payment fraud
Stocks making the biggest moves premarket: Novo Nordisk, FedEx, Nike, Starbucks, MicroStrategy and more
Warren Buffett’s Berkshire Hathaway scoops up Occidental and other stocks during sell-off
Elon Musk endorses far-right Alternative for Germany party in upcoming election
Bitcoin trades around $97,000, recovers from earlier losses
Tesla reverses losses to turn higher in a volatile week for the EV stock